OPM announces its first-half 2024 results and provides an update on its clinical developments, and its financial situation

OPM announces its first-half 2024 results and provides an update on its clinical developments, and its financial situation

Dijon (France), September 25, 2024, at 6:00pm CEST– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced its financial results for the first half of 2024, approved by the Board of Directors on September 25, 2024.